621 reports of this reaction
1.3% of all EMTRICITABINE AND TENOFOVIR ALAFENAMIDE reports
#17 most reported adverse reaction
RENAL IMPAIRMENT is the #17 most commonly reported adverse reaction for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, manufactured by Gilead Sciences, Inc.. There are 621 FDA adverse event reports linking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE to RENAL IMPAIRMENT. This represents approximately 1.3% of all 46,639 adverse event reports for this drug.
Patients taking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE who experience renal impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL IMPAIRMENT is a less commonly reported adverse event for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, but still significant enough to appear in the safety profile.
In addition to renal impairment, the following adverse reactions have been reported for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE:
The following drugs have also been linked to renal impairment in FDA adverse event reports:
RENAL IMPAIRMENT has been reported as an adverse event in 621 FDA reports for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL IMPAIRMENT accounts for approximately 1.3% of all adverse event reports for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, making it a notable side effect.
If you experience renal impairment while taking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.